International journal of clinical pharmacology and therapeutics
Pharmacokinetics of the potassium-competitive acid blocker tegoprazan administered by the oral route in healthy Mexicans.
Miriam Del Carmen Carrasco-Portugal, Gisselle Vanessa González-Hernández, Pablo David López-Cartagena, Francisco Javier Flores-Murrieta
Published: 202610.5414/CP204709
Abstract
BACKGROUND: Tegoprazan is a potassium channel inhibitor with an anti-acid secretion effect. It is metabolized by CYP3A4, a cytochrome enzyme the occurrence of which in the Mexican population, differs from that in some other populations. Since the eff…
Preview only. Read the full abstract at the source